食管鳞癌同期放化疗荟萃分析

doi:10.3760/cma.j.issn.1004-4221.2013.06.007

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To analyze the efficacy and toxicities of concurrent chemoradiotherapy (CCRT) in the non-surgical treatment of esophageal squamous cell carcinoma (ESCC) in China and to provide evidence for its clinical application. Methods CNKI and Wanfang Data were searched to identify the randomized controlledor case-controlled trials of CCRT for ESCC. A meta-analysis was performed to evaluate the efficacy and safety of CCRT for ESCC in China. Results A total of 39 randomized controlledor case controlledtrials involving 4161 patients were included in the meta-analysis. The meta-analysis showed that compared with those receiving radiotherapy alone, the ESCC patients receiving CCRT had significantly improved short-term outcomes (OR=2.588, P=0.000) and significantly increased 1-, 3-, and 5-year survival rates (HR=1.995, P=0.000;HR=2.047, P=0.000;HR=2.265, P=0.000), but they also had significantly increased incidence rates of radiation esophagitis (grade ≥3), radiation pneumonia (grade ≥2), and bone marrow suppression (grade ≥3)(OR=4.372, P=0.000;OR=1.962, P=0.005;OR=4.403, P=0.000). Among the ESCC patients receiving CCRT, those treated with paclitaxel-containing regimen had significantly improved short-term outcomes (OR=1.868, P=0.036) and similar 1-and 3-year survival rates (HR=1.087, P=0.781;HR=1.315, P=0.569), as compared with those treated with FP regimen. Conclusions CCRT can significantly improve the short-term outcome and long-term survival in ESCC patients, but it also increases the incidence of toxicities. Paclitaxel-containing regimen has better short-term efficacy than standard FP regimen among ESCC patients receiving CCRT.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Jun
	YU Jin-ming
	JING Shao-wu
	CHENG Yun-jie
	LIU Qing
	WANG Yi
	CAO Feng
	YANG Cong-rong.

Key words： Esophageal neoplasms/concomitant chemoradiotherapy Prognosis Meta analysis

Received: 03 July 2013

Corresponding Authors: YU Jin-ming, Tianjin Medical University, Tianjin 300070, China;Shandong Tumor Hospital, Ji′nan 250117, China;Email:yujinmingsd@yahoo.com.cn

Cite this article:

WANG Jun,YU Jin-ming,JING Shao-wu et al. Concurrent chemoradiotherapy for esophageal squamous cell carcinoma:a meta-analysis[J]. Chinese Journal of Radiation Oncology, 2013, 22(6): 446-449.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2013.06.007 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2013/V22/I6/446

[1] 金建华,许锡元,刘建跃,等.食管癌术后放化疗疗效及其预后因素分析.中华放射肿瘤学杂志,2009,18:113-114.
[2] Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of esophagus. NEJ Med,1992,329:1597-1598.
[3] 赵快乐,施学辉,蒋国梁,等.食管癌后程加速超分割放疗同期化疗的Ⅲ期临床研究.中华放射肿瘤学杂志,2006,15:277-279.
[4] 王澜,王军,韩春,等.食管癌同期放化疗的价值研究.中华放射肿瘤学杂志,2011,20:291-295.
[5] 毕良文,张丽珍,赵滑峰.多西紫杉醇加奈达铂联合同期适形调强放疗治疗食管癌的疗效.中华放射肿瘤学杂志,2012,34:710-711.
[6] 陈尔成,刘盂忠,胡永红,等.同期放化疗与单纯放疗不能手术食管癌的病例对照研究.中华放射肿瘤学杂志,2007,16:416-419.
[7] 柯军,路逵,李阳,等.放疗联合周剂量奈达铂治疗老年食管癌的临床研究.中国肿瘤临床,2011,38:1594-1596.
[8] 李晓丽,邢月明,宋翔,等.中晚期食管癌TCF方案同期放化疗临床观察.中华放射肿瘤学杂志,2008,17:401-402.
[9] 赵永军, 焦会芝. PFL方案同步放射治疗中晚期食管癌前瞻性随机分组临床探讨.中国肿瘤临床, 2008, 35:611-612.
[10] 刘俊, 吕长兴, 王家明. 同步放化疗治疗不能手术的食管癌临床结果.中华放射肿瘤学杂志, 2006, 15:185-187.
[11] 张好, 俞明根, 钱荣誉,等. 食管癌后程加速超分割放疗协同化疗的疗效评价.中华放射肿瘤学杂志, 2006, 15:89-92.
[12] 周绍兵, 刘阳晨, 高飞,等. 同步化疗加后程加速超分割适形放射治疗食管癌.肿瘤防治研究, 2005, 32:515-516.
[13] 林华明, 殷果, 杨海明. 放疗联合同步化疗治疗食管癌的临床研究.肿瘤防治研究, 2005, 32:430-431.
[14] 陈国荣. 化疗与后程加速超分割联合治疗食管癌临床观察.肿瘤, 2005, 25:289-290.
[15] 乔学英, 周道安, 高献书,等. 后程加速超分割放射加顺铂治疗食管癌的临床研究. 中华放射肿瘤学杂志, 2005, 14:395-397.
[16] 王新强, 程秀祯, 王世伟,等. 放疗联合PF方案同步治疗中晚期食管癌. 中华放射肿瘤学杂志, 2005, 14:215.
[17] 仲立新, 贺利民, 张维真,等. 食管癌同步放化疗与单纯超分割放疗的疗效对比观察.肿瘤, 2004, 24:303-304.
[18] 李宏亮, 严研, 杨爱民,等, 紫杉醇同步后程加速超分割方案治疗老年食管癌的近期疗效.肿瘤防治研究, 2011, 38:188-191.
[19] 朱卫国, 于长华, 周锡垒,等. 同期放化疗或单纯放疗治疗区域淋巴结肿大食管癌随机临床研究.肿瘤防治研究, 2010, 37:449-452.
[20] 李国文,樊青霞, 庆明轩,等. DF方案化疗加放疗治疗中晚期食管癌120例报道. 中华放射肿瘤学杂志, 1996, 5:177.
[21] 王兆星, 刘金安, 王经建,等. DNP化疗加放射治疗中晚期食管癌－80例前瞻性随机研究. 中华放射肿瘤学杂志, 1992, 1:89-90.
[22] 黄雪珍, 吴晖, 陈明强,等. 化疗与放疗综合治疗晚期食管癌64例. 癌症, 1997, 16:215-216.
[23] 陈梅, 郑崴, 李云英. 化疗加放疗及单用放疗治疗晚期食管癌82例疗效分析. 肿瘤防治研究, 1996, 23:232-233.
[24] 乔天奎, 乔学英, 王雅棣,等. 卡铂结合放射治疗中晚期食管癌. 中华放射肿瘤学杂志, 1993, 2:149-150.
[25] 安永辉, 杨宝印, 张广恩. 联合化疗与放射相伴治疗240 例食管癌. 中华放射肿瘤学杂志, 1995, 4:17-18.
[26] 陈焕朝, 李长青. 顺铂、平阳霉素与放疗联合治疗中晚期食管癌疗效观察. 肿瘤防治研究, 1998, 25:204-205.
[27] 张汀荣, 赵韬, 徐昕,等. 多西紫杉醇联合顺铂同期放疗治疗局部晚期食管癌的疗效及其毒副反应. 中华肿瘤杂志, 2010, 32:791-794.
[28] 鞠文翠, 王牧民, 黄静. TP与PF方案同期放疗治疗食管癌的疗效对比. 肿瘤防治研究, 2012, 39:1005-1007.
[29] 路平, 梁秋冬, 牛红蕊,等. 放疗同步每周紫杉醇方案与PF方案治疗中晚期食管癌疗效比较. 中华放射肿瘤学杂志, 2007, 16:33-34.
[30] 姚卫华, 路平, 花勤亮,等. 小剂量顺铂和氟尿嘧啶方案同步放射治疗中晚期食管癌. 中华放射肿瘤学杂志, 2005, 14:262-264.
[31] 吴金通, 沈芬, 陈奇松,等. 同步诱导化疗加后程加速超分割放射治疗食管癌. 中华放射肿瘤学杂志, 2003, 12:138.
[32] 高献书, 杨香然, 乔学英,等. 食管癌后程加速超分割放射合并顺铂的临床研究.中华放射肿瘤学杂志, 2002, 11:97-100.
[33] 季斌, 蔡晶, 马煌如,等. 化疗加放射治疗食管癌的前瞻性研究. 中华放射肿瘤学杂志, 2002, 1112-14.
[34] 李维贵, 张德州, 丁金亮,等. 综合治疗中晚期食管癌200例临床分析.中华放射肿瘤学杂志, 2001, 10:273.
[35] 吴剑, 戴慧, 翁欣然,等. 小剂量顺铂对中晚期食管癌放疗增敏作用的近期疗效观察.中国肿瘤临床, 2006, 33:768-770.
[36] 马杰, 李宝生, 于金明,等. 后程加速超分割适形放疗同步化疗治疗食管癌的临床观察.中华肿瘤防治杂志, 2006, 13:766-768.
[37] 陈属波, 缪建华. 奈达铂和5-FU联合放疗治疗中晚期食管癌的临床研究.中华肿瘤防治杂志, 2006, 13:1817-1819.
[38] 朱振胜, 王达, 任晓,等. 中晚期食管癌后程加速超分割放疗加同期化疗的临床研究.肿瘤, 2006, 26:377-379.
[39] 许泽苹, 蔡舜吼, 徐建芳. 食管癌常规分割放疗同期化疗的临床观察.中华肿瘤防治杂志, 2007, 14:799-800.
[40] 师颖瑞, 吴湘玮, 陈艳平,等. 后程加速超分割适形放疗加同步化疗治疗食管癌的临床观察.中华肿瘤防治杂志, 2008, 15:943-945.
[41] 韩晶, 王澜, 韩春,等. 食管癌同期放化疗的临床观察.中华肿瘤防治杂志, 2011, 18:1859-1863.
[42] Al-Sarraf M, Martz K, Herskovic A, et al.Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer:An intergroup study. J Clin Oncol, 1997, 15:277-284.
[43] Cooper JS, Guo MD, Herskovic A, et al.Chemoradiotherapy of locally advanced esophageal cancer:Long-term follow-up of a prospective randomized trial (RTOG 85－01). Radiation Therapy Oncology Group. JAMA, 1999, 281:1623-1627.
[44] Minsky BD,Pajak TF, Ginsberg Rj,et a1.INT 0123(Radiation Therapy Oncology Group 94－05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy. J Clin Oncol, 2002, 20:1167-1174.
[45] Kato K, Muro K, Minashi K. Phase Ⅱ Study of Chemoradiotherapy with 5-fluorouracil and cisplatin for Stage Ⅱ－Ⅲ esophageal squamous cell carcinoma:JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys, 2011, 81:684-690.
[46] Kelsey CR, Chino JP, Willett CG, et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys, 2007, 69:770-776.
[47] Sun Q, Liu C, Zhong H, et al. Multi-center phase Ⅱ trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer. Jpn J Clin Oncol, 2009, 39:237-243.